Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 9DW: Nivolumab + Ipilimumab vs Sorafenib or Lenvatinib in First-Line Advanced HCC
NCT04039607Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2019
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
Phase 3, randomised trial of nivolumab and ipilimumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall Survival at 4 years. Started Sep 2019; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04039607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04039607.